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Epigenetic therapies, including DNA methyltransferase and histone deacetylase (HDAC) inhibitors, are
increasingly being considered to treat hematological malignancies, but their effects on normal hematopoietic
stem cells (HSCs) remain largely unexplored. We compared the effects of several HDAC inhibitors, including
valproic acid (VPA) and trichostatin A (TSA), alone or in combination with 5-aza-20-deoxycytidine (5azaD) on
the expansion of HSCs. VPA induced the highest expansion of CD34þCD90þ cells and progenitor cells
compared with other HDAC inhibitors or the sequential addition of 5azaD/TSA in culture. Xenotransplantation
studies demonstrated that VPA prevents HSC loss, whereas 5azaD/TSA treatment leads to a net expansion of
HSCs that retain serial transplantation ability. 5azaD/TSA-mediated HSC expansion was associated with
increased histone acetylation and transient DNA demethylation, which corresponded with higher gene
transcript levels. However, some genes with increased transcript levels lacked changes in methylation.
Importantly, a global microarray analysis revealed a set of differentially expressed genes in 5azaD/TSA- and
VPA-expanded CD34þ cells that might be involved in the expansion and maintenance of transplantable HSCs,
respectively. In summary, our data indicate that treatment of HSCs with different chromatin-modifying
agents results in either the expansion or maintenance of HSCs, an observation of potential therapeutic
importance.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION
The mechanisms that govern hematopoietic stem cell
(HSC) fate decisions, including self-renewal and differentia-
tion, are likely under tight control but remain potentially
alterable. Self-renewal and differentiation decisions in HSCs
seem to occur independently of cytokines and are postulated
to be predetermined by cell-intrinsic properties [1,2], which
can also be inﬂuenced by external regulatory factors. We
demonstrated that environmental cues likely inﬂuence
intrinsic factors, such as epigenetic events, to inﬂuence HSC
fate choices [3].
The limited number of HSCs within a cord blood (CB) unit
likely contributes to the high rate of graft failure and delayed
engraftment upon CB transplantation, particularly in adults
[4,5]. However, this limitation could be overcome if the
number of transplantable HSCs within a CB unit were
expanded. Studies have led to the identiﬁcation of several
molecules, including notch ligand, prostaglandin E2, pleio-
trophin, and an aryl hydrocarbon receptor antagonist, as
positive stimulators of HSC expansion, although none of
these molecules alone exhibited potency [6-9]. Currentedgments on page 488.
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13.12.562ex vivo expansion strategies in clinical trials using notch
ligand or marrow stromal cell co-culture primarily expand
short-term progenitors and rely on a second unmanipulated
CB graft for long-term blood cell production [7,10].
Epigenetic therapies, including the hypomethylating drug
5-aza-20-deoxycytidine (5azaD) and histone deacetylase
(HDAC) inhibitors, used alone or in combination, are
increasingly being considered for the treatment of cancers,
including hematological malignancies [11,12]. Valproic acid
(VPA) alone or in combinationwith all-trans retinoic acid has
demonstrated potency in inducing cell death in leukemia,
myeloproliferative diseases, and solid tumors [13-15]. How-
ever, the effects of such epigenetic modiﬁers on normal HSCs
are not clear.
We previously demonstrated that the sequential addition
of 5azaD followed by the HDAC inhibitor trichostatin A (TSA)
in CD34þ cell culture expands normal HSCs possessing
marrow repopulation capacity [16,17]. The objective of our
current study was to examine the potency of various
chromatin-modifying agents (CMAs) either alone or in
combination with a DNA methyltransferase inhibitors and to
compare these results with previously established strategies
involving the sequential addition of CMAs, including the
hypomethylating drug 5azaD and the HDAC inhibitor TSA in
culture [18,19]. Toward this goal, we compared the efﬁcacy of
several CMAs, including VPA, TSA, Nicotinamide (NA), sub-
eroylanilide hydroxamic acid (SAHA), and 5azaD as single
agents or in combination to study their ability to expandTransplantation.
N. Mahmud et al. / Biol Blood Marrow Transplant 20 (2014) 480e489 481repopulating HSCs. The potential of various CMAs to alter
normal HSC fate choices has been explored [20-23], but the
ability of VPA to maintain hematopoietic stem/progenitor
cells in culture has not been previously described. The sig-
niﬁcance of our current study is the demonstration that
different CMAs have variable effects on HSC outcomes and
that this difference can be used to identify genes presumably
involved in distinct biological processes, including HSC
expansion or maintenance. More importantly, we show for
the ﬁrst time that various HDAC inhibitors alone or in com-
bination with DNA methyltransferase inhibitors can exert
distinct effects on HSC outcomes in culture, which might be
relevant for the design of future clinical trials using epige-
netic therapy to treat hematological malignancies.
METHODS
Isolation and Culture of CD34þ Cells
Human CB was obtained according to Institutional Review Board
guidelines. Low-density cells (<1.077 g/mL) were obtained by density
centrifugation on Ficoll-Paque (GE Healthcare, Uppsala, Sweden), and
CD34þ cells were immunomagnetically (Miltenyi Biotech, Inc., Auburn, CA)
isolated from this population as described previously [3]. The purity of the
isolated CD34þ cells ranged from 90% to 99%. CD34þ cell expansion culture
with or without CMA was performed in medium containing 30% FBS
(HyClone Laboratories, Logan, UT) supplemented with a cocktail of recom-
binant human cytokines as previously described [3].
Flow Cytometric Analysis
Flow cytometric analysis was conducted as previously described [18]. All
antibodies were purchased from BD Bioscience (San Jose, CA). All analyses
were paired with the corresponding matched isotype control, and at least
10,000 live cells were acquired for each analysis (CellQuest software, Becton
Dickinson San Jose, CA).
Colony-Forming Cell and Cobblestone AreaeForming Cell Assays
Colony-forming cells (CFCs) were assayed by plating cells in semisolid
methyl cellulose (1.1%)-based medium containing 30% FBS (Stem Cell
Technologies, Vancouver, BC, Canada) and a cocktail of recombinant human
cytokines as described previously [3]. The colonies were counted after 14
days [3]. The number of cobblestone areaeforming cells (CAFCs) was
quantitated by plating in a limiting dilution as described previously
[3,24,25].
Nonobese Diabetic/SCID Assays
Immunodeﬁcient nonobese diabetic/ltsz-scid/scid (NOD/SCID) mice
were purchased from Jackson Laboratories (Bar Harbor, ME), and trans-
plantation assays were performed as previously described [3].
RNA Preparation and Real-Time PCR
RNA preparation and real-time quantitative PCR (qPCR) assays were
performed using SYBR Green dye (Life Technologies, Carlsbad, CA) and an
ABI 7500 Fast Real-Time PCR system (Life Technologies) to quantitate gene
expression using reverse-transcribed mRNA as described previously [18].
The primer sequences used in real-time RT-PCR are shown in Supplemental
Table 1.
Chromatin Immunoprecipitation Assays
The chromatin immunoprecipitation assay was conducted using a
commercial assay kit following the manufacturer’s instructions (Millipore,
Billerica, MA) as described previously [26]. Brieﬂy, after 72 hours of culture,
CD34þ cells were cross-linked with formaldehyde, and the cell pellet was
lysed, sonicated to produce genomic fragments, and immunoprecipitated
using an antieacetyl-histone H4 antibody (Millipore, Billerica, MA).
Microarray Studies
Global gene expression microarray studies using a U133 Plus 2.0 array
(Affymetrix, Santa Clara, CA) were performed in collaborationwith the UCLA
Clinical Microarray Core as described previously with minor modiﬁcations
[27]. For more details, please refer to Supplemental Methods, below.
DNA Methylation Analysis
Brieﬂy, genomic DNA was isolated from primary or CMA-expanded
enriched CD34þ cells using the Blood and Cell Culture DNA kit (Qiagen,
Valencia, CA). Genomic DNA was bisulﬁte treated using an EZ MethylationKit (Zymo Research, Irvine, CA), and biotinylated gene-speciﬁc primers or
long interspersed nucleotide element 1 (LINE-1) primers were used to PCR
amplify the regions of interest as described previously [28,29]. DNA
methylation analysis was performed by EpigenDx (Worcester, MA) using
quantitative pyrosequencing and the PSQ-HS96 system according to stan-
dard operating procedures [28]. Biotinylated gene-speciﬁc primers were
developed for the CpG sites near the promoter area as detailed in
Supplemental Table 3, or LINE-1 primers were used to amplify regions of
interest for analysis as described previously [29].
Measurement of Leukotriene B4 by ELISA
The concentration of leukotriene B4 in conditioned medium was
measuredwith an acetylcholine esterase competitive enzyme immunoassay
following themanufacturer’s instructions (Cayman Chemical Co., Ann Arbor,
MI).
Statistical Analysis
Results are expressed as means  standard error (SE) when applicable.
The statistical signiﬁcance (P< .05) between groups was determined using a
2-tailed Student’s t-test.
RESULTS
VPA Induces Signiﬁcant Expansion of CD34þCD90þ Cells
We compared the effects of various CMAs on HSC
expansion using HDAC inhibitors as single agents or in
combination with 5azaD with the effects of the sequential
addition of 5azaD/TSA, a prototype CMA [3], under identical
culture conditions. As shown in Figure 1C, after culture, 1.17%
 .32% of the total nucleated cells exposed to cytokines alone
co-expressed CD34 and CD90, whereas 2%, 5%, 6%, 13%, and
3% of cells cultured with cytokines plus 5azaD, TSA, NA,
5azaD/NA, or SAHA, respectively, co-expressed the CD34 and
CD90 antigens (Figure 1C). Cultures containing VPA, 5azaD/
TSA, or 5azaD/VPA had a higher percentage of CD34þCD90þ
cells compared with control (42.2%  13.5%, 28.2%  3.6%,
and 52.4%  9.5%, respectively) (Figure 1C). Total nucleated
cells were highest in the control culture and lowest in the
culture treated with 5aza/VPA (Figure 1A). Because total
nucleated cells and the proportion of CD34þCD90þ cells
varied signiﬁcantly in cultures containing various CMAs, in
contrast to the control (Figure 1C), the fold expansion of
primitive CD34þCD90þ cells was analyzed in comparison
with their initial numbers before culture (Figure 1D).
Signiﬁcant differences in the expansion of CD34þCD90þ
cells were observed between cultures treated with various
CMAs (Figure 1D). The addition of VPA resulted in a much
higher expansion (64.6  3.7-fold; P ¼ .001; Figure 1D).
However, when VPA was added after 5azaD to the culture
(5azaD/VPA), the expansion of CD34þCD90þ cells decreased
signiﬁcantly (6.4  1.3-fold), despite having the highest
percentage of CD34þCD90þ cells (Figure 1C). VPA treatment
alone provided the maximal expansion of CD34þCD90þ
cells (Figure 1D). Notably, NA (2.1-fold) and SAHA (1.2-fold)
as single agents or in combination with 5azaD (5azaD/NA
[2.2-fold]) did not promote the expansion of CD34þCD90þ
cells relative to 5azaD/TSA or VPA-expanded CB cells.
These data indicate that among the CMAs examined, VPA
and 5azaD/TSA best expand CD34þCD90þ cells. We previ-
ously demonstrated that CD34þCD90þ cells exclusively
retain in vivo hematopoietic repopulation potential [16], but
the repopulation capacity of VPA- or 5azaD/VPA-expanded
cells is not known.
Functional Potency of CMA-Expanded CB Grafts
To determine the correlation between the expansion of
CD34þCD90þ cells and their in vitro functional potential,
CFC and CAFC assays were performed using CB cells that
were expanded using various CMAs. Figure 1E depicts the
P 
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Figure 1. Effects of various CMAs on the expansion of CB cells after 9 days of culture. (A) The total nucleated cells (TNCs) per well after culture are shown as a bar
graph. (B) Representative ﬂow cytometric analysis of CB cells using mAbs for CD34 and CD90 or a matched isotype control. (C) The proportion of CD34þCD90þ cells
after culture. The proportion of CD34þCD90þ cells in NA-, 5azaD/NA-, and SAHA-treated cultures are representative of 2 experiments, whereas all other CMAs tested
are representative of 3 independent experiments. (D) The fold expansion of TNCs, CD34þ cells, and CD34þCD90þ cells was determined by dividing the total number
of viable cells expressing the phenotype at the end of the culture by the input number of viable cells expressing the same phenotype. For example, in the present
study, the expansion culture was initiated with 50,000 CD34þ cells (TNCs) with 1.4  104 CD34þCD90þ cells per well (day 0). The addition of 5azaD/TSA in the
culture yielded 0.53  106 TNCs per well with 28.17% CD34þCD90þ cells, which represents a 10.7-fold expansion of CD34þCD90þ cells after 9 days. However, in the
absence of 5azaD/TSA (cytokine alone), the culture yielded 2.3  106 TNCs per well with only 1.17% cells expressing CD34þCD90þ, resulting in 2.7  104
CD34þCD90þ cells per well, which is a mere 1.9-fold expansion. The bar graph represents the mean  SE of 3 independent experiments, except for NA, 5azaD/NA,
and SAHA, which represent the mean of 2 independent experiments. The cytokines included 100 ng/mL recombinant stem cell factor (SCF), 100 ng/mL FLT3 ligand
(FL), 100 ng/mL thrombopoietin (TPO), and 50 ng/mL IL-3 during the ﬁrst 48 hours. At 48 hours, fresh medium containing 30% FBS and identical cytokine con-
centrations were added; IL-3 was omitted. All cytokines were purchased from Cell Genix USA (Antioch, IL). (E-H) The in vitro functional potential of CMA-expanded CB
cells was determined by CFC and CAFC assays. (E) The PE and the fold (F) expansion of primitive CFU-mix colonies and the frequency (G) and fold (H) expansion of
CAFCs from their initial number (before culture) after ex vivo expansion of CD34þ cells are shown. Data are expressed as the mean  SE of 3 independent exper-
iments. The fold expansion of CFU-mix colonies and CAFCs were determined by dividing the absolute number of CFU-mix colonies and CAFCs assayed from the
culture product (day 9) by the absolute number of CFU-mix/CAFCs assayed from the input primary uncultured CD34þ cells (day 0). The CAFC frequency was
calculated by the minimization of a chi regression using limiting dilution analyses with 95% statistical precision with L-Calc software (Stem Cell Technologies) as
described previously [3,24,25]. P was calculated by Student’s T Test and is relative to Cytokines Alone. * P  .05 ** P  .01 y P  .005 z P  .001.
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Table 1
Hematopoietic Reconstitution Potential of Various CMA-Expanded CB Cells
in NOD/SCID Mice
No. of NOD/SCID
Mice Engrafted/
No.
Transplanted
Human
CD45þ Cells
Primary CB (day 0) 2/5 0.15%, 0.3%
Cytokines alone (day 9) 0/5 NA
Cytokines þ 5azaD/TSA
(day 9)
5/5 0.2%, 0.47%, 4%, 15%, 18%
Cytokines þ VPA (day 9) 2/7 0.11%, 0.14%
Cytokines þ 5azaD/VPA
(day 9)
0/6 NA
NA indicates not available.
NOD/SCID mice were transplanted with CD34þ-enriched primary uncul-
tured cells containing 10,000 CD34þCD90þ cells or the progeny of 10,000
CD34þCD90þ cells after expansion culture were injected per mouse i.v.
using the tail vein as described previously [3]. Because the number of
CD34þCD90þ cells injected was relatively low, the degree of chimerism is
also expected to be low, as described previously [3]. The percentage of
human CD45þ cells indicates the percent of human hematopoietic cells
present in the bone marrow of each mouse at 8 weeks after trans-
plantation. The speciﬁcity of the human mAb allows the detection of hu-
man blood cells with a cut-off value >0.1% by ﬂow cytometry, as described
previously [3].
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(CFU)-mix colonies derived from expanded CB cells in the
presence of various CMAs. The PE (%) of the CFU-mix colonies
derived from VPA- and 5azaD/TSA- expanded cells was
0.77 %  0.18 % and 1.9 %  0.23%, respectively, whereas the
PE of the CFU-mix colonies derived from cells expanded in
the absence of CMA was only 0.1%  0.06% (Figure 1E).
CB cells expanded in the presence of 5azaD/TSA or 5azaD/
VPA displayed the highest PE for CFU-mix colonies. However,
the total nucleated cell output of each culture condition was
signiﬁcantly different. Although 5azaD/VPA-expanded cells
had the highest PE, the expansion of CFU-mix colonies after
culture was the lowest (Figure 1F). Cultures receiving VPA or
5azaD/TSA had the highest degree of expansion of primitive
CFU-mix colonies (13.3  4.7 and 12.4  3.4-fold, respec-
tively), as shown in Figure 1F. The frequency of the more
primitive long-term in vitro hematopoietic progenitors,
CAFCs, in 5azaD/TSA-expanded cells was approximately
4-fold greater than that in VPA-expanded cells (52.7  10.37
versus 14.67  0.74, Figure 1G).Table 2
Frequency of SCID Mouse Repopulating Cells (SRCs) in Uncultured Primary or CMA
CD34þCD90þ Cells or Its Expanded
Products Injected/Mouse
No. of NOD/SCID Mice Engrafted/No. Tra
Day 0 Day 9 Cytoki
1000 ND ND
2000 0/6 ND
5000 3/8 ND
10,000 2/5 0/5
20,000 3/5 0/3
50,000 4/5 2/5
100,000 ND 2/3
SRC frequency 1 in 22,000 (95% CI,
1/11,722 to 1/41,293)
1 in 123,315*
1/46,617 to
ND indicates not detectable; CI, conﬁdence interval.
NOD/SCIDmice (n¼ 94) were transplantedwith increasing doses of CD34þCD90þ c
the expanded products of 5azaD/TSA- or VPA-expanded CD34þ cell cultures ini
7 independent limiting dilution experiments using CD34þ cells from single CB units
experiments were calculated using the single-hit Poisson model, and a maximum
previously [3]. The speciﬁcity of the human mAb allows the detection of human b
* The SRC frequency was determined at identical time points using the same sta
published (reprinted with permission [3]).The CAFC frequency of CB cells expanded in the absence
of CMA (control) was 1.1  0.64, and the CAFC frequency of
5azaD/VPA-expanded cells was 62.9  7.8 per 10,000 cells
plated. When we determined the absolute number of CAFCs,
VPA- and 5azaD/TSA-expanded cultures had the highest
degree of CAFC expansion (8.4  1.6-fold and 10.5  1.5-fold,
respectively; Figure 1H). VPA-expanded cultures contained
6-fold more CD34þCD90þ cells than 5azaD/TSA; therefore,
these cultures would be expected to be more enriched in
CFCs and CAFCs. However, despite the greater number of
CD34þCD90þ cells, the expansion of CFU-mix colonies and
CAFCs derived fromVPAwere at best comparablewith that of
the 5azaD/TSA cultures (Figure 1D, F, and H). Our data indi-
cate that the expansion of CD34þCD90þ cells after 5azaD/
TSA but not VPA treatment correlates with their functional
potential as demonstrated by the expansion of both CFCs and
CAFCs.VPA Maintains Transplantable HSCs in Culture
NOD/SCID mice were transplanted with primary uncul-
tured CD34þ cells or the product of an equivalent starting
number of CD34þ cells after expansionwith cytokines alone,
5azaD/TSA, VPA, or 5azaD/VPA. After transplantation, 5 mice
receiving cells from cultures containing only cytokines and 6
mice receiving cells from cultures treated with cytokines and
5azaD/VPA were devoid of human hematopoietic cell
chimerism (Table 1). By contrast, all 7 mice receiving grafts
from cultures expanded with 5azaD/TSA showed evidence of
human multilineage hematopoietic engraftment (Table 1).
The cells from cultures expanded with cytokines and VPA
were capable of human hematopoietic engraftment in 2 of
7 mice, with a minimally detectable level of chimerism
(Table 1). Primary CD34þ cells or CD34þ cells expandedwith
5azaD/TSA and VPA retained their ability to differentiate into
both myeloid and lymphoid lineages after transplantation
(data not shown).
Independently, the SCID mouse repopulating cell (SRC)
frequency was determined by transplanting uncultured or
CMA-expanded cells in a limiting dilution as described pre-
viously [3]. The frequency of SRCs was 1 in 22,000 in primary
uncultured CD34þCD90þ cells and 1 in 21,720 in VPA-
expanded CD34þCD90þ cells (Table 2). Cultures containing
only cytokines displayed an SRC frequency of 1 in 123,315.
5azaD/TSA-expanded cultures had an SRC frequency of 1 in-Expanded CB Cells
nsplanted
nes Alone Day 9 Cytokines þ 5azaD/TSA Day 9 Cytokines þ VPA
0/3 ND
2/4 0/7
4/5 2/5
5/5 2/7
5/5 5/8
ND ND
ND ND
(95% CI,
1/326,200)
1 in 3147* (95% CI, 1/1602
to 1/6189)
1 in 21,720 (95% CI,
1/11,160 to 1/42,269)
ells estimated to be present in the puriﬁed uncultured CD34þ cell fraction or
tiated with the same initial number of CD34þCD90þ cells. The data from
(CB units were not pooled) were pooled. The data from the limiting dilution
likelihood estimator was used to determine the SRC frequency as described
lood cells with a cut-off value >0.1%, as described previously [3].
rting material and experimental conditions, but some data were previously
Table 3
Serial Transplant Capacities of VPA-Expanded CB Cells in Contrast to Un-
cultured Primary CB Grafts
Graft Primary Transplants* Secondary Transplantsy
Primary Mouse
BM Chimerism
(% human)
Secondary Mouse
BM Chimerism
(% human)
1 Primary CB 15.1 ND
2 Primary CB 29.6 10.5
3 Primary CB 16.3 0.11%
4 Primary CB 48.5 ND
5 Primary CB 25.3 ND
6 VPA expanded 0.60% ND
7 VPA expanded 1.0 ND
8 VPA expanded 0.30% ND
9 VPA expanded 5.6 ND
10 VPA expanded 1.0 ND
BM indicates bone marrow; ND, not detectable.
Both primary and secondary hosts for the serial transplant studies received
a single i.p. injection (200 mg per mouse) of TM-b1 (BD Biosciences Phar-
Mingen, San Diego, CA) within 4 hours after total body irradiation (300 cGy)
to eliminate the residual natural killer cell activity of the mice, as described
previously [18]. For secondary transplantation, two thirds of the unfrac-
tionated BM of each primary mouse, which exhibited multilineage human
hematopoietic engraftment after transplantation, were injected into sec-
ondary recipients without further enrichment of human cells as described
previously [18]. The speciﬁcity of the human mAb allows the detection of
human blood cells with a cut-off value >0.1%, as described previously [3].
*1  104 primary uncultured CD34þCD90þ cells or an equal initial
number of CD34þCD90þ cells expanded with VPA and cytokines for 9 days
were injected into sublethally irradiated primary NOD/SCID mice.
y10 to 30  106 unseparated BM cells from primary engrafting mice were
injected into sublethally irradiated secondary NOD/SCID recipients, which
were killed 7 weeks later.
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absolute number of SRCs in comparison with the input
CD34þCD90þ cells. By contrast, although VPA treatment
prevented the loss of SRCs, it merely maintained SRC
numbers during ex vivo culture despite lacking any detect-
able bone marrow homing defects (data not shown).
The serial transplantation of unfractionated bone marrow
cells from recipients engrafted with uncultured CD34þ cells
resulted in hematopoietic engraftment in 2 of 5 mice. By
contrast, primary recipients engrafted with an equivalent
input number of CD34þCD90þ cells expanded with VPA did
exhibit engraftment in any of the 5 secondary hosts (Table 3).
Using identical culture conditions and the same number of
transplanted cells, we previously demonstrated that 5azaD/
TSA-expanded CB cells retain serial transplant ability [18].
These results indicate that unlike 5azaD/TSA, VPA-expanded
cells likely expand short-term HSCs.Gene Expression, DNA Methylation, and Histone
Acetylation in Expanded CB Cells
Because the proportion of CD34þ cells expanded in the
presence or absence of 5azaD/TSA in the culture is signiﬁ-
cantly different (36.7%  4.4% versus 7.0%  0.4%), in the
current study, we reisolated CD34þ cells after culture for
qPCR studies to avoid the inﬂuence of relatively mature
CD34- cells. As shown in Figure 2A, treatment with 5azaD/
TSA or VPA resulted in an increase in the expression levels of
several genes, including GATA2, HoxB4, Bmi1, and Ezh2. The
expression of differentiation-associated genes, including
GATA1, may be due to the activation of gene expression. The
transcript levels of the CDK inhibitor p21 were increased in
5azaD/TSA- and VPA-expanded CD34þ cells. Reduced p21
levels are generally associated with a shorter G1/S transition.
The expression levels of genes generally implicated in HSCself-renewal, including Ezh2, HoxB4, and Bmi1, were not
signiﬁcantly different in 5azaD/TSA-treated cells, and
enriched reisolated CD34þ cells expanded with VPA
(Figure 2A).
We quantiﬁed the global methylation of genomic DNA in
uncultured and culture-expanded, enriched CD34þ cells
using an assay for LINE-1 methylation, which is a surrogate
marker of genome-wide global methylation [29]. Interest-
ingly, LINE-1 studies of 5azaD/TSA-expanded CD34þ cells
indicated the transient hypomethylation of DNA because the
methylation levels returned to pretreatment levels after
culture (Figure 2B) and corresponded with the recovery of
DNA methyltransferase 1 transcript and protein levels (data
not shown) [30]. Moreover, for some genes, the increase in
transcript levels correlated with histone H4 acetylation, as
determined by chromatin immunoprecipitation assays
(Figure 2C). Increased histone H4 acetylation in the promoter
regions of the HoxB4, Bmi1, and GATA2 genes corresponded
with their increased expression in 5azaD/TSA-expanded
CD34þ cells compared with control cultures. Notably, VPA-
expanded CD34þ cells exhibited intermediate levels of his-
tone H4 acetylation of the Bmi1 and HoxB4 genes compared
with control and 5azaD/TSA cultures.
Identiﬁcation of Putative HSC Expansion and
Maintenance Genes
Global gene expression in expanded CD34þ cells was
analyzed to identify distinct sets of genes linked with the
following in vivo hematopoietic repopulation functions:
expansion (5azaD/TSA), maintenance (VPA), or loss (control),
as demonstrated by xeno-transplantation assays. We used
expanded, enriched CD34þ cell populations after culture
with different CMA treatments in comparison with uncul-
tured CD34þ cells for themicroarray studies. A heat mapwas
generated by analyzing the differential gene expression of
primary (day 0) or expanded CD34þ cells from 5 different
CD34þ cell populations. As shown in Figure 3A, 88 differ-
entially expressed genes passed with a correlation coefﬁ-
cient, r, of 0.85, indicating a high level of correlation between
the expression pattern of these genes and hematopoietic
reconstitution capacity. Furthermore, principal component
analysis of these 88 genes also revealed that the CD34þ cells
with and without hematopoietic reconstitution capacity
each are clustered together into distinct groups (Figure 3B).
The above ﬁndings demonstrate a correlation between
hematopoietic reconstitution function and gene expression.
This result led us to hypothesize that putative HSC mainte-
nance- and expansion-related candidate genes could be
identiﬁed by pairing differential expression with the in vivo
hematopoietic reconstitution function of the test cell pop-
ulations. Considering the limitations of using a rare cell
population for microarray analysis, we used CD34þ CB cells,
which are commonly used for microarray studies [6,31-33].
We postulated that 113 common differentially expressed
genes identiﬁed between 5azaD/TSA-expanded CD34þ cells
versus control cells and 5azaD/TSA- versus VPA-expanded
CD34þ cells were related to HSC expansion (Figure 3C).
Similarly, 278 common genes presumably related to HSC
maintenance (VPA) were identiﬁed as differentially ex-
pressed between the pairs 5azaD/TSA-expanded versus
control and VPA-expanded versus control CD34þ cells
(Figure 3C).
Intriguingly, ingenuity pathway analysis linked 113 HSC
“expansion” genes (Supplementary Table 4) with molecules
involved in inﬂammation and lipidmetabolism, distinct from
Figure 2. Gene expression, DNA methylation, and histone acetylation in CMA-expanded CD34þ cells. (A) Gene transcript levels were examined in reisolated CD34þ
enriched cells after expansion culture (day 9) in the presence of 5azaD/TSA, VPA, or a control. TRIzol (Invitrogen, Carlsbad, CA) was used to extract total RNA from
CD34þ cells or CD34þ cells enriched after expansion culture as described previously [18]. To quantitate the transcribed levels of various genes in CD34þ cells, we
performed PCR ampliﬁcation using an ABI 7500 Fast Detector (Life Technologies) using standard PCR cycling conditions. A standard curve method was used for
relative mRNA quantiﬁcation, and all results for gene expression were normalized to the expression of GAPDH as an internal calibrator. The difference in transcript
levels between control and either 5azaD/TSA- or VPA-expanded CD34þ cells was statistically signiﬁcant for all genes tested, except S100A8 (control versus VPA P ¼
.09). However, the difference in transcript levels between 5azaD/TSA- and VPA-expanded CD34þ cells was not statistically signiﬁcant, except for GATA2 (P ¼ .03). All
data presented here represent the mean  SE of 3 independent experiments, except for p21, which represents the mean  SE of 2 independent experiments. (B) A
LINE-1 assay showing global methylation levels in repetitive DNA elements using bisulﬁte-treated genomic DNA from enriched CD34þ cells. LINE-1 methylation was
expressed as the mean  SE of % methylation for 4 CpG sites using genomic DNA from primary or CMA-expanded reisolated CD34þ cells from 2 replicate experiments
(D0 and D3) or 1 experiment (D9). LINE-1 element PCR was used to perform a pyrosequencing-based methylation analysis as described previously [33]. The degree of
methylation was expressed for each DNA locus as the percentage of methylated cytosines over the sum of methylated and unmethylated cytosines. For example, the
percentage of methylation for LINE-1 fragments or individual genes was analyzed as an artiﬁcial cytosine (C)/thymine (T) SNP, in which C represents methylated C and
T represents unmethylated C. The ratio of the C peak to (CþT) is expressed as the percentage of methylation. Methylation (%) data were expressed as the mean  SE of
4 CpG sites for the LINE-1 assays. Non-CpG cytosines were used as an internal quality control (QC) for bisulfate conversion, and the average values of multiple CpG
sites were used for statistical analysis. **P < .005 relative to the prior time point. (C) Chromatin immunoprecipitation assays showing histone H4 acetylation levels in
chromatin prepared from CD34þ cells expanded in 5azaD/TSA, VPA, or control cultures. Chromatin was immunoprecipitated using an anti-acetylated histone H4
antibody, and chromatin-bound DNA was PCR ampliﬁed using promoter-speciﬁc primers. GAPDH was used as an internal control. No-antibody and matched-isotype
controls were included as negative controls, and input chromatin was included as a positive control. The precipitated chromatin-bound DNAwas PCR ampliﬁed using
the primers for speciﬁc genes as shown in Supplementary Table 2. The ampliﬁed PCR fragments were then analyzed on a 1.2% agarose gel. P was calculated by
Student’s T Test and is relative to Cytokines Alone. * P  .05 ** P  .01 y P  .005 z P  .001.
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We validated the transcript levels of several genes selected
from the HSC expansion and maintenance gene sets using
real-time qPCR (Figure 4A,B). The thrombin receptor F2RL2
gene transcript was represented in both the HSC expansion
and HSC maintenance gene lists. However, our PCR valida-
tion data indicated that F2RL2 is differentially expressed in
CD34þ cells expanded with 5azaD/TSA or VPA (Figure 4B).
Similarly, Cyp11A1 is not in the putative HSC maintenance
group, consistent with our PCR validation, which demon-
strated lower transcript levels in VPA-expanded CD34þ cells
than in 5azaD/TSA-expanded CD34þ cells (Figure 4A).Differentially expressed genes representative of the HSC
expansion list included the calcium-binding protein S100A8,
whereas those representatives of the HSC maintenance
list included Alox5, a gene involved in arachidonic acid
metabolism and the production of leukotrienes. Both genes
function as inﬂammatory mediators, and their transcript
levels were increased in 5azaD/TSA- as well as in VPA-
expanded CD34þ cells compared with controls. The higher
expression of Alox5, ALDH1A1, and BMPR1A in VPA-expanded
CD34þ cells is also consistent with our microarray results
because these genes are some of the 278 HSC maintenance-
related genes.
Figure 3. Identiﬁcation of the gene expression proﬁle of enriched CD34þ cells expanded in 5azaD/TSA, VPA, or control cultures linked with in vivo hematopoietic
reconstitution function using global microarray analyses. Here, the expanded CD34þ cells used for microarray studies were also deﬁned by their functional capacity
from xeno-transplant studies using immunodeﬁcient mice. For example, CD34þ cells expanded in 5azaD/TSA and VPA presumably represent the expansion and
maintenance of in vivo repopulating HSCs, respectively, as shown by SRC frequency analyses (see Table 2). (A) Heat map showing genes whose differential expression
correlates with the in vivo hematopoietic reconstitution capacity of expanded/unmanipulated CD34þ cells. Primary uncultured and 5azaD/TSA- or VPA-expanded
reisolated CD34þ cell populations that possess in vivo hematopoietic reconstitution potential were arbitrarily assigned a regenerative capacity value of 2,
whereas nonregenerative (lacking hematopoietic reconstitution capacity) samples (D9 control and D9 TSA/5azaD reverse CMA sequence) were assigned a value of
0 (0.01). Using this analysis, 88 genes displayed an r > 0.85, indicating a high correlation between gene expression and regenerative capacity. (B) Principal component
analysis of the 88 genes shown in the heat map analysis was used to perform principal component analysis mapping of primary or ex vivo expanded enriched CD34þ
cells linked with hematopoietic regenerative capacity. (C) Identiﬁcation of common genes based on their differential expression in expanded CD34þ cells from 5azaD/
TSA, VPA, and control cultures. Using this strategy, 113 HSC expansion genes that were differentially expressed between 5azaD/TSA versus control and 5azaD/TSA
versus VPA were identiﬁed. Similarly, 278 HSC maintenance genes were identiﬁed that were differentially expressed between 5azaD/TSA versus control and VPA
versus control cultured CD34þ cells.
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We quantiﬁed the methylation of CpG sites in the pro-
moters of speciﬁc genes by pyrosequencing. Genes impli-
cated in HSC self-renewal, including HoxB4 and GATA2,
almost completely lacked methylation, even though their
transcript levels increased after CMA treatment in culture
(Figure 4C). Interestingly, genes with a role in hematopoiesis,
including GATA1, weremethylated in uncultured CD34þ cells
and control cultures, whereas 5azaD/TSA treatment resulted
in signiﬁcant demethylation, which corresponded with
their relatively higher transcript levels (Figure 4C). Although
VPA resulted in minimal demethylation of the GATA1 gene
after culture (Figure 4C), increased GATA1 transcript levels
were also observed, indicating a possible indirect effect
(Figure 2A).
Finally, the transcript levels of several genes not known
for their role in hematopoiesis were not only increased after
CMA treatment in culture but were exclusively associated
with the HSC expansion gene list from the microarray ana-
lyses (113 genes; eg, S100A8). Consistently, 5azaD/TSA-
expanded CD34þ cells displayed a signiﬁcant reduction in
the methylation levels of the S100A8 and Cyp11A1 gene
promoter sites (Figure 4C). Cyp11A1 gene transcript levels
were also signiﬁcantly higher in 5azaD/TSA-expanded
CD34þ cells compared with CD34þ cells expanded with VPA
or control cultures (5azaD/TSA versus control, P < .001;
5azaD/TSA versus VPA, P < .001). VPA-expanded CD34þ cells
almost completely lacked any changes in the methylation of
the S100A8 gene promoter sites, despite increased transcript
levels. Similarly, although the transcript level of Alox5 in5azaD/TSA-expanded CD34þ cells was increased, Alox5 also
lacked detectable changes in methylation.
In addition, an ingenuity pathway analysis of the 88 genes
identiﬁed from heat map analyses of the CD34þ cell pop-
ulations possessing or lacking hematopoietic reconstitution
capacity (Figure 3A) revealed inﬂammation as a top network
(Figure 4D, Supplementary Tables 6.1 and 6.2.). Interestingly,
an ELISA assay revealed that the level of the inﬂammatory
mediator leukotriene B4 was increased in the conditioned
medium from the expansion of CD34þ cells with 5azaD/TSA
and VPA compared with conditioned medium from control
cells (Figure 4E). Leukotriene B4 is synthesized from arach-
idonic acid by the dual action of the Alox5 gene product, 5-
lipoxygenase, and LTA4 hydrolase. Both microarray analyses
and qPCR validation data indicated that the Alox5 transcript
levels were relatively higher in CD34þ cells expanded with
VPA than those expanded with 5azaD/TSA.
DISCUSSION
The present study demonstrates that epigenetics plays a
role in silencing genes that are likely involved in the regu-
lation of HSC maintenance and expansion in culture. We
demonstrate that this process can be circumvented by the
use of CMAs in culture, which activate genes by direct or
indirect mechanisms, resulting in distinct HSC fate choices,
expansion or maintenance. Our transplant studies demon-
strate that although sequential ex vivo treatment of CD34þ
cells with 5azaD/TSA expands transplantable HSCs that
possess serial transplant capacity [18], VPA treatment only
permits the maintenance of HSCs that lack serial transplant
Figure 4. Validation of genes represented in putative HSC expansion or maintenance groups. (A) Validation by qPCR of genes identiﬁed by global microarray that are
presumably associated with HSC expansion or (B) maintenance. The mean  SE of 3 independent experiments is shown. (C) The methylation levels of the promoter
CpG sites of several genes that were differentially expressed between the putative HSC expansion and HSC maintenance groups were analyzed by pyrosequencing.
Primary uncultured CD34þ cells (day 0) and reisolated enriched CD34þ cells expanded in 5azaD/TSA (day 3) or VPA (day 3) were used to obtain genomic DNA, which
was bisulﬁte treated and used to measure methylation levels. Data are displayed as the mean %  SE of 3 to 11 CpG sites near the promoter area of each gene from 2
independent samples, except pu.1 (6 CpG) and Cyp11A1 (5 CpG), for which only 1 sample was analyzed. (D) Ingenuity pathway analysis revealed the top signaling
networks among the 88 differentially expressed genes based on the presence or absence of in vivo hematopoietic regeneration capacity. (E) The concentration of
leukotriene B4 (LTB4), an inﬂammatory mediator, in conditioned medium from CB cells expanded in the presence or absence of CMA was measured by an acetyl-
cholinesterase competitive ELISA. Data are expressed as the mean  SE of triplicate wells from 3 independent experiments (*P < .05 relative to control).
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strategies will likely provide a solution to generate a com-
posite graft containing augmented numbers of both short-
term hematopoietic stem/progenitors and long-term HSCs
expanded by VPA and 5azaD/TSA, respectively.
Curiously, SAHA and NA in culture displayed poor cell
survival. In particular, when VPA was added after 5azaD, thiscombination was detrimental to CD34þCD90þ cell expan-
sion in culture, and these cells failed to display hematopoi-
etic reconstitution capacity after transplantation. Because
many of these agents are being used in cancer treatment, the
role of CMA in normal HSC viability as well as their potential
use in cancer therapeutics may have important implications.
Because CB cells expanded in the absence of a CMA display
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that CMAs act by preventing the down-regulation of genes
crucial for the retention of HSC function during culture
by promoter hypomethylation. 5azaD/TSA-expanded cells
displayed a 7-fold increase in SRCs compared with
VPA-expanded cultures, despite having 6-fold fewer
CD34þCD90þ cells. We previously demonstrated that after
5azaD/TSA treatment in culture, repopulating HSCs reside
exclusively within the CD34þCD90þ cell population [3].
However, most VPA-expanded CD34þCD90þ cells were
devoid of SRC, CAFC, and, to some extent, CFC capability. This
discordance between the phenotype and function of VPA-
expanded cells and, more importantly, the increase in the
absolute number of SRCsmediated by 5azaD/TSA but not VPA
has not been described previously. Although the regulation
of cellular differentiation based on HDAC isoform selectivity
remains to be fully elucidated [34], whether 5azaD/TSA and
VPA inhibit distinct HDAC isoforms, resulting in the survival
and proliferation of long-term and short-term HSCs,
respectively, will be the focus of future studies.
Furthermore, the gene expression pattern in expanded
CD34þ cells results at least in part from epigenetic modiﬁ-
cations that include changes in promoter CpG site methyl-
ation and histone acetylation. Differential gene expression
from our global microarray studies revealed distinct gene
expression patterns associated with functional HSC expan-
sion or maintenance. Indeed, the addition of CMAs to the
culture was associated with increased transcript levels of
polycomb group genes including Ezh2 and Bmi1, which are
known to regulate HSC self-renewal [18,35-37]. Using a
candidate gene approach, we were unable to discern differ-
ences in the expression levels of HSC self-renewal genes
between CD34þ cells expanded in 5azaD/TSA and VPA.
Alternatively, variations in the composition of subtypes of
cells within CD34þ populations may have masked differ-
ences in gene expression.
Our studies indicate that CMAs result in both direct and
indirect effects early in culture, which contribute to a tran-
scriptome state that promotes HSC expansion or mainte-
nance. For example, as a direct result of CMA treatment, a
signiﬁcant reduction in methylation levels was detected at
the S100A8, Cyp11A1, and GATA1 gene promoter sites, corre-
sponding with their increased transcript levels in CD34þ
cells expanded in 5azaD/TSA. Furthermore, heat map anal-
ysis highlighted a differential gene expression pattern be-
tween CD34þ cells possessing or lacking in vivo marrow
repopulation potential. Our data also show that CpG islands
near the promoter areas of genes, including HoxB4 and
GATA2, do not display signiﬁcant changes in methylation,
suggesting their increased transcript levels in CMA-
expanded CD34þ cells are likely due to indirect effects.
We hypothesize that temporal effects, including early
epigenetic modiﬁcations, lead to changes in transcription
factor expression that directly or indirectly promote sym-
metrical or asymmetrical HSC divisions and ultimately result
in HSC expansion or maintenance. The analysis of differential
gene expressionusing globalmicroarray studies, such as those
in the present study,may help to identify such gene networks.
Identifying a gene expression signature linked with in vivo
blood regeneration capacity has signiﬁcant clinical applica-
tions. To expandHSCs, bothexpansionandmaintenancegenes
are likely necessary. The 19 genes that were shared between
the putative HSC expansion- and maintenance-related genes
included genes involved in lipid metabolism, such as F2RL2,
MPEG1, ALDH1A1, and BMPR1A. These shared genes likelypossess dual functions in HSCmaintenance and expansion. In
future studies, the functional roles of these distinct sets of
genes that are presumably involved in HSC maintenance and
expansionwill need to be tested further.
Expression proﬁling data indicate that the differential
expression of gene transcripts, such as Cyp11A1, Alox5, and
F2RL2, may serve as biomarkers that indicate the successful
expansion or maintenance of transplantable HSCs. Interest-
ingly, S100A8, which was more highly expressed in CMA-
expanded CD34þ cells, has been shown to be a Toll-like
receptor 4 agonist [38]. Toll-like receptor 4 expression plays
a role in the maintenance and proliferation of endothelial
progenitor cells [39]. The transientdemethylationof CpG sites
corresponding with higher transcript levels of inﬂammation/
stress-associated genes and the increase in inﬂammatory
mediators in CMA-expanded cultures is consistentwith a role
of these molecules in HSC expansion or maintenance. This
idea is consistent with the inﬂuence of systemic infection on
HSC cycling and the role of interferonas a positive regulator of
HSC proliferation [40]. Further studies are needed to deter-
mine whether CMAs inﬂuence HSC expansion or mainte-
nance by promoting the expression of inﬂammatory and
other stress response pathway genes.
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